1. Web site: http://statepi.jhsph.edu/macs/macs.html Prepared by CAMACS Fax: 410-955-7587 May 2011 The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute and the National Heart, Lung and Blood Institute. UO1-AI-35042, UL1- RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041. DOSSIER Updates May 2012

3. CAMACS Planning and design of studies Coordination of data acquisition –Form development –Codebooks –Data transfer Standardization and data management –Edits and updates –Data security Data analysis, statistical computing and methodological research September 1995

5. , AB (negs)

6. Continuous Outcome Ascertainment Seroconversion (seronegatives only) Clinical Outcomes (medical records confirmation) –AIDS diagnoses –Non-AIDS diagnoses Cardiovascular disease Cerebrovascular disease Kidney disease Liver disease Lung infection, bacterima, septicemia Malignancies Neurologic –Mortality November 2004

10. Composition & Size of Cohort May 2011 Visit (Calendar year) # Participants (thousands) Seronegative Seroconverter Seroprevalent * 1710 have been administratively censored

11. MACS Database (as of May 2012) May 2012 Publications ( published & in press ) 11,229 Participants 6,992 Person-Years 89,752 Variables 12,305 Repository aliquots 1,638,409 (plasma, serum, cells, urine) HIV+ HIV- Person-Visits58,287 74,588 CD4 Measurements53,641 59,619 HIV RNA Measurements35,822 1,218

15. Retention of LA MACS Participants (including active and those who died; through 09/30/07) % HIV-% HIV+% Seroconverters European-American 92.6 94.0 87.3 African-American 67.4 78.6 100 Hispanic-American 76.1 84.3 81 Total 85.3 90.4 87.3 Combined = 1530/1728=88.5%

16. Incidence* of Seroconversion in the MACS by Center September 1995 Baltimore Chicago Pittsburgh Los Angeles Kingsley, Zhou,..., Muñoz - AJE 1991 (update) * Incidence = # of seroconverters per 1,000 person-semesters

17. June 1997

18. Likelihood of Developing AIDS in Three Years Mellors, Muñoz,..., Rinaldo - Ann Int Med 1997 June 1997 >30K >55K 10K – 30K 20K – 55K 3K – 10K 7K – 20K 501 – 3K 1501 – 7K <500 bDNA <1501 RT-PCR Plasma Viral Load (copies/ml in thousands) CD4+ T-lymphocyte Count (cells/mm 3 )

19. Proportion Surviving AIDS by Year of Diagnosis Assumed currently alive at 6/30/99 if contacted since 6/30/98 Jacobson, Kirby,..., Schrager - AJE 1993 (update) October 1999

21. MACS Subgroups of Particular Interest Long-term seropositive individuals with minimal declines in CD4 levels Seropositive individuals with rapid declines in CD4 levels Long-term survivors with low CD4 levels Seroconverters High-risk seronegatives Seropositives on treatment >55 years old

22. Key Factors in the Success of the MACS The commitment and sacrifice of the participants The staff members of the MACS Strong laboratory support

23. UCLA MACS Staff John Oishi, Study Coordinator Kevin Barrett, Data Manager/Programmer Max Hechter, Coordinator Charles Doran, Administrative Specialist Nicole Hadjioannou, SRA, Clinical Follow-up

24. MACS Clinic Staff LA Men’s Study, Wilshire Site –Dennis Miles, Site Manager –May Htike, Lead Examiner –Daniel Cheng, SRA, Senior Interviewer –Tuan Nguyen, Examiner –Alan Ernst, Interviewer Los Angeles Gay & Lesbian Center –Eduardo Mercado, Coordinator –Ray Mercado, Coordinator Harbor-UCLA Medical Center –Carlos Aquino, Coordinator –Lisa Siquieros, Assistant Coordinator –Gilbert Papilla, Assistant Coordinator

25. LA MACS Investigators Beth JamiesonAndrew Levine John FaheyJordan Lake Anthony ButchOtto Yang Steve YoungPeter Anton Najib AzizElizabeth Breen Oto MartinezKarl Goodkin Rita EffrosMathew Wright Barbara VisscherRichard Wight Jonathan BraunPamina Gorbach Eric MillerSteve Shoptaw Mallory WittZuofeng Zhang Dorothy WileyShenaz Hussain Harry Vinters Many students